Zulvac 1+8 Bovis

RSS

Authorised

This medicine is authorised for use in the European Union

inactivated bluetongue virus, serotypes 1 and 8
MedicineVeterinaryAuthorised

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

български (BG) (93.36 kB - PDF)

Bekijk

español (ES) (81.97 kB - PDF)

Bekijk

čeština (CS) (93.99 kB - PDF)

Bekijk

dansk (DA) (83.34 kB - PDF)

Bekijk

Deutsch (DE) (82.76 kB - PDF)

Bekijk

eesti (ET) (82.18 kB - PDF)

Bekijk

ελληνικά (EL) (93.76 kB - PDF)

Bekijk

français (FR) (82.44 kB - PDF)

Bekijk

Gaeilge (GA) (83.57 kB - PDF)

Bekijk

hrvatski (HR) (92.27 kB - PDF)

Bekijk

italiano (IT) (82.29 kB - PDF)

Bekijk

latviešu (LV) (94.29 kB - PDF)

Bekijk

lietuvių (LT) (94.03 kB - PDF)

Bekijk

magyar (HU) (94.15 kB - PDF)

Bekijk

Malti (MT) (95.95 kB - PDF)

Bekijk

Nederlands (NL) (82.05 kB - PDF)

Bekijk

polski (PL) (95.62 kB - PDF)

Bekijk

português (PT) (83.01 kB - PDF)

Bekijk

română (RO) (94.17 kB - PDF)

Bekijk

slovenčina (SK) (94.08 kB - PDF)

Bekijk

slovenščina (SL) (82.27 kB - PDF)

Bekijk

suomi (FI) (81.54 kB - PDF)

Bekijk

svenska (SV) (82.05 kB - PDF)

Bekijk

Íslenska (IS) (83.29 kB - PDF)

Bekijk

norsk (NO) (82 kB - PDF)

Bekijk

Product information

български (BG) (91.78 kB - PDF)

Bekijk

español (ES) (81.51 kB - PDF)

Bekijk

čeština (CS) (92.48 kB - PDF)

Bekijk

dansk (DA) (82.05 kB - PDF)

Bekijk

Deutsch (DE) (81.72 kB - PDF)

Bekijk

eesti (ET) (81.22 kB - PDF)

Bekijk

ελληνικά (EL) (91.79 kB - PDF)

Bekijk

français (FR) (81.63 kB - PDF)

Bekijk

Gaeilge (GA) (81.36 kB - PDF)

Bekijk

hrvatski (HR) (91.56 kB - PDF)

Bekijk

italiano (IT) (81.76 kB - PDF)

Bekijk

latviešu (LV) (92.14 kB - PDF)

Bekijk

lietuvių (LT) (92.19 kB - PDF)

Bekijk

magyar (HU) (92.76 kB - PDF)

Bekijk

Malti (MT) (93.86 kB - PDF)

Bekijk

Nederlands (NL) (81.15 kB - PDF)

Bekijk

polski (PL) (93.22 kB - PDF)

Bekijk

português (PT) (82.53 kB - PDF)

Bekijk

română (RO) (91.73 kB - PDF)

Bekijk

slovenčina (SK) (81.75 kB - PDF)

Bekijk

slovenščina (SL) (81.76 kB - PDF)

Bekijk

suomi (FI) (81.11 kB - PDF)

Bekijk

svenska (SV) (81.47 kB - PDF)

Bekijk

Íslenska (IS) (81.52 kB - PDF)

Bekijk

norsk (NO) (81.52 kB - PDF)

Bekijk

български (BG) (93.36 kB - PDF)

Bekijk

español (ES) (81.97 kB - PDF)

Bekijk

čeština (CS) (93.99 kB - PDF)

Bekijk

dansk (DA) (83.34 kB - PDF)

Bekijk

Deutsch (DE) (82.76 kB - PDF)

Bekijk

eesti (ET) (82.18 kB - PDF)

Bekijk

ελληνικά (EL) (93.76 kB - PDF)

Bekijk

français (FR) (82.44 kB - PDF)

Bekijk

Gaeilge (GA) (83.57 kB - PDF)

Bekijk

hrvatski (HR) (92.27 kB - PDF)

Bekijk

italiano (IT) (82.29 kB - PDF)

Bekijk

latviešu (LV) (94.29 kB - PDF)

Bekijk

lietuvių (LT) (94.03 kB - PDF)

Bekijk

magyar (HU) (94.15 kB - PDF)

Bekijk

Malti (MT) (95.95 kB - PDF)

Bekijk

Nederlands (NL) (82.05 kB - PDF)

Bekijk

polski (PL) (95.62 kB - PDF)

Bekijk

português (PT) (83.01 kB - PDF)

Bekijk

română (RO) (94.17 kB - PDF)

Bekijk

slovenčina (SK) (94.08 kB - PDF)

Bekijk

slovenščina (SL) (82.27 kB - PDF)

Bekijk

suomi (FI) (81.54 kB - PDF)

Bekijk

svenska (SV) (82.05 kB - PDF)

Bekijk

Íslenska (IS) (83.29 kB - PDF)

Bekijk

norsk (NO) (82 kB - PDF)

Bekijk

Product details

Name of medicine
Zulvac 1+8 Bovis
Active substance
  • inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP
  • inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotypes 1 and 8

Pharmacotherapeutic group

  • Immunologicals
  • Immunologicals for Bovidae
  • Cattle
  • Inactivated viral vaccines
  • bluetongue virus

Authorisation details

EMA product number
EMEA/V/C/002473

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Assessment history

This page was last updated on

Share this page